Produção Nacional
Revisado por pares
18F-FDG PET-CT for Surveillance of Brazilian Patients with Li-Fraumeni Syndrome
2015; Frontiers Media; Volume: 5; Linguagem: Inglês
10.3389/fonc.2015.00038
ISSN2234-943X
AutoresSonia Tereza Santos Nogueira, Eduardo Nóbrega Pereira Lima, Amanda França de Nóbrega, Ivone Do Carmo Gonçalves Torres, Marcelo Cavicchioli, Pierre Hainaut, Maria Isabel Achatz,
Tópico(s)Cancer, Hypoxia, and Metabolism
ResumoPurpose To evaluate the effectiveness of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) for detecting early cancer in carriers of germline TP53 mutation, the genetic defect underlying Li-Fraumeni and related syndromes (LFS/LFL) which predisposes to many forms of cancer throughout life. Patients and Methods A total of 30 adult patients from 6 families with germline TP53 mutations were recruited. These patients did not have a diagnosis of cancer in the 24 months preceding the study. Anomalous concentrations from whole-body 18F-FDG-PET/CT were assessed by two independent experts. Suspicious lesions were excised and subjected to pathological examination. Results A total of 6/30 patients showed abnormal 18F-FDG-concentration. Confirmation studies revealed three cases of cancer, including one lung cancer, one ovarian cancer and one disseminated breast cancer. Three patients had non-malignant lesions (one Bartholin's cyst and two cases of reactive lymph nodes). Conclusions 18F-FDG-PET/CT is effective in detecting cancer in subjects who are asymptomatic according to current screening guidelines. These results further suggest that 18F-FDG-PET/CT is an appropriate method for surveillance of cancer risk in TP53 mutation carriers.
Referência(s)